Market closed
Apollomics Inc./$APLM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Ticker
$APLM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
13
Website
Apollomics Inc. Metrics
BasicAdvanced
$6.2M
-
-$52.80
0.94
-
Price and volume
Market cap
$6.2M
Beta
0.94
52-week high
$11.60
52-week low
$4.95
Average daily volume
35K
Financial strength
Current ratio
1.388
Quick ratio
1.339
Long term debt to equity
15.07
Total debt to equity
19.86
Interest coverage (TTM)
-229.76%
Management effectiveness
Return on assets (TTM)
-75.07%
Return on equity (TTM)
-233.67%
Valuation
Price to revenue (TTM)
29.003
Price to book
1.28
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-0.2
Growth
Revenue change (TTM)
-75.88%
Earnings per share change (TTM)
-77.24%
3-year revenue growth (CAGR)
362.61%
3-year earnings per share growth (CAGR)
-46.10%
Apollomics Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Apollomics Inc. stock?
Apollomics Inc. (APLM) has a market cap of $6.2M as of April 16, 2025.
What is the P/E ratio for Apollomics Inc. stock?
The price to earnings (P/E) ratio for Apollomics Inc. (APLM) stock is 0 as of April 16, 2025.
Does Apollomics Inc. stock pay dividends?
No, Apollomics Inc. (APLM) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Apollomics Inc. dividend payment date?
Apollomics Inc. (APLM) stock does not pay dividends to its shareholders.
What is the beta indicator for Apollomics Inc.?
Apollomics Inc. (APLM) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.